3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
2
Gastrointestinal
2
Sarcoma
1
Plasma cell
1
Other hematologic neoplasm
1
Lymphoid
1
CNS
1
Conditions
Vascular Diseases
1
Paraproteinemias
1
Neoplasms, Plasma Cell
1
Neoplasms by Histologic Type
1
Neoplasms
1
Multiple Myeloma
1
Lymphoproliferative Disorders
1
Lymphoma
1
Lymphatic Diseases
1
Immunoproliferative Disorders
1
Hemorrhagic Disorders
1
Hematologic Diseases
1
Cardiovascular Diseases
1
Blood Protein Disorders
1
Interventions
Cyclophosphamide
211
Rituximab
193
fludarabine
134
fludarabine phosphate
91
Vincristine
78
Cytarabine
66
Etoposide
65
Doxorubicin
61
Dexamethasone
60
Lenalidomide
59
venetoclax
56
ibrutinib
55
Prednisone
54
Bendamustine Hydrochloride
51
obinutuzumab
48
Filgrastim
46
Bortezomib
46
Specimen Handling
42
pembrolizumab
39
Gemcitabine
39
Methotrexate
38
Melphalan
38
Biopsy
38
Peripheral Blood Stem Cell Transplantation
32
Magnetic Resonance Spectroscopy
32
Azacitidine
31
Vorinostat
29
Nivolumab
29
Calcium Dobesilate
29
Clofarabine
26
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1
×
ficlatuzumab
×
Lymphoid
×
Clear all
NCT00725634
2014-01-27
P05538
AVEO Pharmaceuticals, Inc.
Phase 1
Completed
41 enrolled